The short version of LC-MS fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-09-07. Anything still debated is marked as such rather than presented as settled.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
== Medical uses == Prednisone is used for many different autoimmune diseases and inflammatory conditions, including asthma, gout, COPD, CIDP, rheumatic disorders, allergic disorders, ulcerative colitis and Crohn's disease, granulomatosis with polyangiitis, adrenocortical insufficiency, hypercalcemia due to cancer, thyroiditis, laryngitis, severe tuberculosis, hives, eczema, lipid pneumonitis, pericarditis, multiple sclerosis, nephrotic syndrome, sarcoidosis, to relieve the effects of shingles, lupus, myasthenia gravis, poison oak exposure, Ménière's disease, autoimmune hepatitis, giant cell arteritis, the Herxheimer reaction that is common during the treatment of syphilis, Duchenne muscular dystrophy, uveitis, and as part of a drug regimen to prevent rejection after organ transplant. Prednisone has also been used in the treatment of migraine headaches and cluster headaches and for severe aphthous ulcer. Prednisone is used as an antitumor drug. Prednisone is often also prescribed as a form of treatment for sudden sensorineural hearing loss (SSNHL). Prednisone can be used in the treatment of decompensated heart failure to increase renal responsiveness to diuretics, especially in heart failure patients with refractory diuretic resistance with large doses of loop diuretics. In terms of the mechanism of action for this purpose: prednisone, a glucocorticoid, can improve renal responsiveness to atrial natriuretic peptide by increasing the density of natriuretic peptide receptor type A in the renal inner medullary collecting duct, thereby inducing a potent diuresis.
Crocetta is crossed by large and modern avenues, such as Corso Duca degli Abruzzi, Corso Galileo Ferraris, and Corso Einaudi. These avenues feature long rows of trees, symbolic of Turin's typical urbanity. However, the most popular avenue is Corso De Gasperi, which, albeit smaller than other avenues of the district, hosts one of the most fashionable open markets of the city, the so-called Mercato della Crocetta, in which it is possible to find some discounted branded clothing among the more popular ones. The Western border of Crocetta is instead an example of contemporary architecture. The huge avenue, made up of Corso Mediterraneo and Corso Castelfidardo, is part of Spina Centrale boulevard and was recently built over the old railway (now undergrounded): as a result, the avenue is very large (up to 60 m (200 ft)) and modern, having been rebuilt with valuable materials, including a characteristic lighting system supported by white high poles. This avenue hosts some examples of contemporary art, such as Mario Merz's Igloo fountain or the Per Kirkeby's Opera per Torino monument in Largo Orbassano. The East side of the district is also known as Borgo San Secondo named after the church of the same name standing in Via San Secondo, a major street in the neighbourhood. This is near Porta Nuova railway station and is older than the rest of the district, featuring several apartment buildings from the late 19th century, to include the birthplace and home of author Primo Levi on Corso Re Umberto. A local open market is held in Piazza San Secondo and along Via Legnano.
== Scientific approach == In xenobiology, the aim is to design and construct biological systems that differ from their natural counterparts on one or more fundamental levels. Ideally these new-to-nature organisms would be different in every possible biochemical aspect exhibiting a very different genetic code. The long-term goal is to construct a cell that would store its genetic information not in DNA but in an alternative informational polymer consisting of xeno nucleic acids (XNA), different base pairs, using non-canonical amino acids and an altered genetic code. So far cells have been constructed that incorporate only one or two of these features.
Bryant Park contains a Beaux-Arts granite restroom structure on the northern border, along 42nd Street. There are two facilities, one for men and women, both of which are 315 square feet (29.3 m2). These were built in 1911 along with the NYPL Main Branch, but due to the park's landmark status, they cannot be expanded. The exterior of each building contains a frieze with garland motifs. After being closed in the mid-1960s, they were restored by Kupiec & Koutsomitis and reopened in 1992. The restrooms have been described as being among the city's best. A subsequent renovation in 2006 solidified their status as, in the words of then-New York City Parks Commissioner Adrian Benepe, "the gold standard for park comfort stations." The restrooms were renovated again in 2017. Following the 2017 renovation, the restrooms contained rotating artworks selected from a collection of 225 works, as well as fresh flowers, classical music, attendants, and automatic toilets and faucets.
Sources: en.wikipedia.org
Psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) Psilocin (4-hydroxy-N,N-dimethyltryptamine) Baeocystin (4-phosphoryloxy-N-methyltryptamine) Norbaeocystin (4-phosphoryloxytryptamine) Aeruginascin (N,N,N-trimethyl-4-phosphoryloxytryptamine) The potential psychoactivity of other compounds other than psilocybin and psilocin has been speculated but not confirmed. The concentrations of psilocin and psilocybin, as determined by high-performance liquid chromatography, are in the range of 0.14–0.42% (wet weight) and 0.37–1.30% (dry weight) in the whole mushroom 0.17–0.78% (wet weight) and 0.44–1.35% (dry weight) in the cap, and 0.09%–0.30% (wet weight) and 0.05–1.27% (dry weight) in the stem, respectively. For quickly and practically measuring the psychoactive contents of most healthy Psilocybe cubensis varieties, it can generally be assumed that there is approximately 15 mg (± 5 mg) of psilocybin per gram of dried mushroom. Furthermore, due to factors such as age and storage method, the psilocybin and psilocin content of a given sample of mushrooms will vary. Individual body composition, brain chemistry and psychological predisposition play a significant role in determining appropriate doses. For a modest psychedelic effect, a minimum of one gram of dried Psilocybe cubensis mushrooms is ingested orally, 0.25–1 gram is usually sufficient to produce a mild effect, 1–2.5 grams usually provides a moderate effect and 2.5 grams and higher usually produces strong effects.
The youth set-up did not replicate the success of the late 1990s and early 2000s, though Arsenal consistently finished fourth or higher in the league between 2006 and 2011. The club earnt a reputation of functioning as a "feeder club" to bigger teams, as Wenger struggled to keep hold of his best players. He described this period as "very sensitive" because of the financial restrictions that came with the stadium move. Since the 2011–12 season, Wenger has reverted to buying proven talent, and blended experience with youth in domestic cup competitions. Arsenal have benefited from increased revenue since the Emirates move, and negotiating new sponsorship deals has allowed Wenger to make marquee signings such as Özil, Sánchez, Granit Xhaka, Alexandre Lacazette and Pierre-Emerick Aubameyang. Observing Wenger's transfer policy in 2009, Sir Alex Ferguson commented that it lacked balance and needed defensive players to solidify the Arsenal team. The players Wenger recruits have often been criticised for their character and leadership capabilities; footballer Joey Barton suggested it was because the manager discouraged them from commanding: "Sometimes you need someone to galvanise and that might be a shouter and bawler. It may not be Arsene's way, but I think they lack that." Wenger is perceived as frugal given his inactivity in transfer windows, but he has denied the stereotype: "Of course people say always to buy but you cannot make careers [and you cannot] buy every time you have an injured player. You know I have the wrong reputation. I'm not scared to spend money.
The Iranian foreign ministry said it was merely reviewing proposals from the US sent through mediators. On 25 March, Pakistani officials delivered a "15-point proposal" from the US to Iran, detailing a ceasefire plan. The US proposal included an end to Iran's nuclear program, limits on its missiles, reopening the Strait of Hormuz, restrictions on Iran's support for armed groups, and sanctions relief for Iran. The Iranians rejected the US proposal, with an anonymous official telling Press TV that "Iran will end the war when it decides to do so and when its own conditions are met". The Iranians issued a "5-point counter-proposal", including an end to US-Israeli attacks on Iran and pro-Iranian forces in Lebanon and Iraq, security guarantees to prevent future Israeli and US aggression, war reparations, and international recognition of Iranian sovereignty over the Strait of Hormuz. On 31 March, Pakistan and China delivered a "5 point initiative" for peace, calling for an immediate end to all hostilities and allowance of humanitarian aid into the region. Trump claimed on 1 April 2026 that Iran had just asked the US for a ceasefire and that the US would consider it once the Strait of Hormuz was "open, free, and clear. Until then, we are blasting Iran into oblivion ... back to the Stone Ages!". Iran's foreign ministry called the claim "false and baseless". The IRGC said the strait "will not be opened to the enemies of this nation through the ridiculous spectacle by the president of the US".
Tarlov cysts, also known as perineural cysts, are cerebrospinal fluid (CSF)-filled lesions that most commonly develop in the sacral region of the spinal canal (S1–S5), and less frequently in the cervical, thoracic, or lumbar spine. These cysts form as dilations of the nerve root sheath near the dorsal root ganglion, specifically within the perineural space between the endoneurium and perineurium. A defining feature is that the cyst walls contain nerve fibers, which often line the inner cavity of the cyst itself. This involvement of neural elements distinguishes Tarlov cysts from other extradural meningeal cysts, such as meningeal diverticula, which do not contain nerve fibers. The etiology of these cysts is not well understood; some current theories explaining this phenomenon include increased spinal fluid pressure, filling of congenital cysts with one-way valves, and/or inflammation in response to trauma and disease. They are named after an American neurosurgeon Isadore Tarlov, who described them in 1938. These cysts are often detected during MRI or CT scans. They are also observed using magnetic resonance neurography with communicating subarachnoid cysts of the spinal meninges. Cysts with diameters of 1cm or larger are more likely to be symptomatic; although cysts of any size may be symptomatic dependent on location and etiology. Some 40% of patients with symptomatic Tarlov cysts can associate a history of trauma or childbirth.
==== Calcitonin gene-related peptide (CGRP) inhibitors ==== Atogepant (AGN-241689; Aquipta; MK-8031; Qulipta) – calcitonin gene-related peptide receptor (CGRPR) antagonist – migraine [131] Eptinezumab (ALD-403; Lu-AG09221; Vyepti) – monoclonal antibody against calcitonin gene-related peptide (CGRP) – migraine [132] Erenumab (Aimovig; AMG-334) – monoclonal antibody against calcitonin gene-related peptide receptor (CGRPR) – migraine [133] Fremanezumab (Ajovy; LBR-101; PF-04427429; PF-4427429; RN-307; TEV-48125) – monoclonal antibody against calcitonin gene-related peptide (CGRP) – migraine [134] Galcanezumab (Emgality; LY-2951742) – monoclonal antibody against calcitonin gene-related peptide (CGRP) – cluster headache, migraine [135] Rimegepant (BHV-3000; BMS-927711; Nurtec; Vydura) – calcitonin gene-related peptide receptor (CGRPR) antagonist – migraine [136] Ubrogepant (MK-1602; Ubrelvy) – calcitonin gene-related peptide receptor (CGRPR) antagonist – migraine [137] Zavegepant (BHV-3500; BMS-742413; PF-07930207; Vazegepant; Zavzpret) – calcitonin gene-related peptide receptor (CGRPR) antagonist – migraine [138]
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
Research-grade SR9009 is typically stored frozen at about minus twenty degrees Celsius, protected from light and moisture. Stock solutions are often kept in aliquots to avoid repeated freeze-thaw cycles. Specific storage conditions should follow the supplier's documentation.